HCW - AMRN: Europe Can Present Second Wind for Vascepa, Despite Programís Infancy (Buy PT 10) | AMRN Message Board Posts

Amarin Corporation plc

  AMRN website

AMRN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  8243 of 8383  at  2/27/2021 4:01:58 PM  by

ex_hacker202


 In response to msg 8239 by  JBWIN
view thread

Re: HCW - AMRN: Europe Can Present Second Wind for Vascepa, Despite Programís Infancy (Buy PT 10)

 Specifically informed by: (1) Amarin’s displayed domestic launch aptitude from Vascepa’s expanded label in cardiovascular (CV) risk reduction;
 
Ha! Word should be ineptitude! And if AMRN 2029 EPS is projected to be a meager 95 cents, discounted or not, this analysis would convince me to NOT buy the stock - that's pitiful earnings, only $400M/yr.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board








Financial Market Data provided by
.
Loading...